LTC3154561I2 - - Google Patents

Info

Publication number
LTC3154561I2
LTC3154561I2 LTPA2024514C LTPA2024514C LTC3154561I2 LT C3154561 I2 LTC3154561 I2 LT C3154561I2 LT PA2024514 C LTPA2024514 C LT PA2024514C LT PA2024514 C LTPA2024514 C LT PA2024514C LT C3154561 I2 LTC3154561 I2 LT C3154561I2
Authority
LT
Lithuania
Application number
LTPA2024514C
Other languages
Lithuanian (lt)
Original Assignee
Ra Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC3154561(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ra Pharmaceuticals, Inc. filed Critical Ra Pharmaceuticals, Inc.
Publication of LTPA2024514I1 publication Critical patent/LTPA2024514I1/lt
Publication of LTC3154561I2 publication Critical patent/LTC3154561I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTPA2024514C 2014-06-12 2024-05-21 LTC3154561I2 (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US201562108772P 2015-01-28 2015-01-28
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity

Publications (2)

Publication Number Publication Date
LTPA2024514I1 LTPA2024514I1 (enExample) 2024-06-10
LTC3154561I2 true LTC3154561I2 (enExample) 2025-11-10

Family

ID=54834568

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP19194070.9T LT3628680T (lt) 2014-06-12 2015-06-12 Komplemento aktyvumo moduliavimas
LT15807069T LT3154561T (lt) 2014-06-12 2015-06-12 Komplemento veiklos moduliavimas
LTPA2024514C LTC3154561I2 (enExample) 2014-06-12 2024-05-21

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP19194070.9T LT3628680T (lt) 2014-06-12 2015-06-12 Komplemento aktyvumo moduliavimas
LT15807069T LT3154561T (lt) 2014-06-12 2015-06-12 Komplemento veiklos moduliavimas

Country Status (31)

Country Link
US (7) US10106579B2 (enExample)
EP (4) EP4223317A3 (enExample)
JP (4) JP6432954B2 (enExample)
KR (3) KR101981532B1 (enExample)
CN (3) CN111187338B (enExample)
AP (1) AP2016009612A0 (enExample)
AU (3) AU2015274482B2 (enExample)
BR (3) BR122023024819A2 (enExample)
CA (3) CA3241273A1 (enExample)
CY (3) CY1122227T1 (enExample)
DK (2) DK3154561T3 (enExample)
ES (2) ES2750556T3 (enExample)
FI (1) FIC20240015I1 (enExample)
FR (1) FR24C1022I2 (enExample)
HR (2) HRP20191763T1 (enExample)
HU (3) HUE045646T2 (enExample)
IL (3) IL249093B (enExample)
LT (3) LT3628680T (enExample)
MX (2) MX2016016449A (enExample)
NL (1) NL301275I2 (enExample)
NO (1) NO2024023I1 (enExample)
NZ (1) NZ727420A (enExample)
PL (2) PL3628680T3 (enExample)
PT (2) PT3628680T (enExample)
RS (2) RS62428B1 (enExample)
RU (1) RU2670988C2 (enExample)
SG (1) SG11201610222UA (enExample)
SI (2) SI3628680T1 (enExample)
SM (2) SMT201900568T1 (enExample)
WO (1) WO2015191951A2 (enExample)
ZA (3) ZA201706379B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101981532B1 (ko) * 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
TWI745320B (zh) 2015-12-16 2021-11-11 美商Ｒａ製藥公司 補體活性之調節劑
US11026945B2 (en) 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2019246387A1 (en) * 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
ES3013570T3 (en) 2018-06-21 2025-04-14 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
BR112021007083A2 (pt) 2018-10-22 2021-08-03 Ra Pharmaceuticals, Inc tratamento de doença neurológica com zilucoplan
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
MX2021013010A (es) * 2019-04-24 2022-01-18 Ra Pharmaceuticals Inc Composiciones y metodos para modular la actividad del complemento.
CA3140193A1 (en) 2019-06-04 2020-12-10 Ra Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors
WO2021050885A1 (en) 2019-09-12 2021-03-18 Ra Pharmaceuticals, Inc. Neurological disease treatment with complement inhibitors
MX2022006514A (es) 2019-12-26 2022-07-11 Eisai R&D Man Co Ltd Composicion farmaceutica que contiene un acido ribonucleico de doble hebra que inhibe la expresion de c5 de complemento.
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment
AU2022347024A1 (en) 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing
WO2024039636A1 (en) * 2022-08-16 2024-02-22 Ps Therapy, Inc. Methods of use for disulfiram and metabolites thereof
CN120981230A (zh) * 2023-03-31 2025-11-18 弗莱克斯塞思知识产权控股有限责任公司 杂芳基抗降解剂

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2641081A1 (enExample) * 1988-12-23 1990-06-29 Medgenix Group
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
WO1994028424A1 (en) 1993-05-28 1994-12-08 Chiron Corporation Method for selection of biologically active peptide sequences
PT710243E (pt) 1993-06-29 2000-11-30 Ferring Bv Sintese melhorada de peptidos ciclicos.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
JP3683282B2 (ja) 1996-10-17 2005-08-17 三菱化学株式会社 遺伝子型と表現型の対応付け分子及びその利用
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
DK0971946T3 (da) 1997-01-21 2006-10-30 Gen Hospital Corp Selektion af proteiner ved anvendelse af RNA-protein-fusioner
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
AU5471199A (en) 1998-08-07 2000-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
WO2003074992A2 (en) * 2002-03-01 2003-09-12 Mds Proteomics Inc. Phosphorylated proteins and uses related thereto
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
ES2392511T3 (es) * 2002-11-15 2012-12-11 Musc Foundation For Research Development Moduladores de complemento dianas sobre el receptor 2 de complemento
KR20100038477A (ko) * 2003-05-05 2010-04-14 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
MXPA05011886A (es) 2003-05-15 2006-02-17 Tanox Inc Metodos y composiciones para la prevencion y tratamiento de septicemia.
EP1667702A2 (en) * 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
WO2005053612A2 (en) 2003-11-26 2005-06-16 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
WO2006066258A2 (en) * 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
CA2595902C (en) 2005-01-24 2017-08-22 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
JP2009530299A (ja) 2006-03-15 2009-08-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体のインヒビターによる発作性夜間血色素尿症患者の処置
EP1876183A1 (en) * 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
PL3028716T3 (pl) 2006-10-10 2021-03-08 Regenesance B.V. Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
JP2010520309A (ja) 2007-03-06 2010-06-10 ノボ・ノルデイスク・エー／エス 出血関連性炎症を治療するための補体系活性化の調節
EP2129681A2 (en) 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
US20080269318A1 (en) 2007-04-30 2008-10-30 Carmelo Romano Treatment of age-related macular degeneration using inhibitors of complement factor d
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
KR20150080007A (ko) 2007-10-02 2015-07-08 포텐시아 팔마큐티칼스, 인크. 겔로부터 콤스타틴 유사체의 지속적 운반
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20100093624A1 (en) 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
CN102170906B (zh) * 2008-08-05 2014-07-30 诺华股份有限公司 靶定补体蛋白c5的抗体的组合物和方法
AU2009290137A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
KR20110094029A (ko) 2008-11-10 2011-08-19 알렉시온 파마슈티칼스, 인코포레이티드 보체-관련된 장애를 치료하는 방법 및 조성물
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
KR101759895B1 (ko) 2009-10-16 2017-07-20 오메로스 코포레이션 Ｍａｓｐ－2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
HUE027229T2 (en) 2009-12-16 2016-08-29 Novo Nordisk As Double acylated glp-1 derivatives
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2545072B1 (en) 2010-03-12 2017-11-22 The Regents of The University of California Lipid-peptide-polymer conjugates and nanoparticles thereof
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
JP2014509859A (ja) * 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US20140296147A1 (en) * 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
AU2013222836B2 (en) 2012-02-20 2017-07-20 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement C5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
MX2016011862A (es) 2014-03-20 2016-12-05 Inflarx Gmbh Inhibidores de c5a para el tratamiento de la neumonia viral.
KR101981532B1 (ko) * 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
JP2018502870A (ja) 2015-01-21 2018-02-01 パシラ ファーマシューティカルズ インコーポレーテッド トラネキサム酸の多小胞リポソーム処方物
WO2016123371A1 (en) * 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
TWI745320B (zh) 2015-12-16 2021-11-11 美商Ｒａ製藥公司 補體活性之調節劑
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3682016A4 (en) 2017-09-11 2021-06-02 RA Pharmaceuticals, Inc. FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
CA3084043A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
MX2021013010A (es) 2019-04-24 2022-01-18 Ra Pharmaceuticals Inc Composiciones y metodos para modular la actividad del complemento.

Also Published As

Publication number Publication date
CA2949985C (en) 2023-10-17
CN106456701A (zh) 2017-02-22
FR24C1022I2 (fr) 2025-05-23
US11535650B1 (en) 2022-12-27
US20170137468A1 (en) 2017-05-18
RU2018136750A (ru) 2018-11-06
AU2015274482B2 (en) 2018-11-08
CY1124595T1 (el) 2022-07-22
IL273746B (en) 2021-03-25
WO2015191951A2 (en) 2015-12-17
AU2021204313B2 (en) 2024-01-04
US11014965B2 (en) 2021-05-25
HUE055931T2 (hu) 2022-01-28
ES2750556T3 (es) 2020-03-26
KR102503319B1 (ko) 2023-02-28
EP4223317A2 (en) 2023-08-09
US10106579B2 (en) 2018-10-23
BR112016029076A2 (pt) 2018-06-05
PL3628680T3 (pl) 2022-01-10
LT3628680T (lt) 2021-11-25
JP2017523232A (ja) 2017-08-17
RS62428B1 (sr) 2021-11-30
IL281264A (en) 2021-04-29
KR20190057420A (ko) 2019-05-28
JP6432954B2 (ja) 2018-12-05
CA3174909A1 (en) 2015-12-17
KR20220002727A (ko) 2022-01-06
EP3154561A2 (en) 2017-04-19
AP2016009612A0 (en) 2016-12-31
SMT201900568T1 (it) 2019-11-13
KR101981532B1 (ko) 2019-09-02
EP3628680A1 (en) 2020-04-01
JP7454545B2 (ja) 2024-03-22
HRP20211561T8 (hr) 2022-03-04
BR112016029076B1 (pt) 2024-02-15
CY1122227T1 (el) 2020-11-25
EP3154561B1 (en) 2019-09-04
CN111187338B (zh) 2024-08-02
PL3154561T3 (pl) 2019-12-31
AU2019200828A1 (en) 2019-02-28
EP3628680B1 (en) 2021-09-08
HUS2400015I1 (hu) 2024-06-28
JP6770043B2 (ja) 2020-10-14
EP4223317A3 (en) 2023-09-27
NZ727420A (en) 2018-06-29
NZ761610A (en) 2024-03-22
IL249093A0 (en) 2017-01-31
RS59353B1 (sr) 2019-10-31
CN106456701B (zh) 2020-01-07
NZ736573A (en) 2024-03-22
FR24C1022I1 (fr) 2024-07-19
DK3154561T3 (da) 2019-10-07
AU2021204313A1 (en) 2021-07-22
HRP20191763T1 (hr) 2019-12-27
FIC20240015I1 (fi) 2024-05-28
NL301275I2 (nl) 2024-06-20
BR112016029076A8 (pt) 2022-02-08
US10208089B2 (en) 2019-02-19
AU2015274482A1 (en) 2017-01-12
JP7002597B2 (ja) 2022-02-04
EP3154561A4 (en) 2018-04-18
CA2949985A1 (en) 2015-12-17
BR122021025449B1 (pt) 2024-02-15
RU2670988C2 (ru) 2018-10-29
US20210246167A1 (en) 2021-08-12
CY2024015I1 (el) 2024-12-13
HUE045646T2 (hu) 2020-01-28
BR122023024819A2 (pt) 2023-12-26
IL249093B (en) 2020-05-31
ES2895029T3 (es) 2022-02-17
SI3628680T1 (sl) 2021-12-31
SG11201610222UA (en) 2017-01-27
LTPA2024514I1 (enExample) 2024-06-10
PT3154561T (pt) 2019-10-25
ZA201706379B (en) 2018-12-19
AU2019200828B2 (en) 2021-04-08
SMT202100588T1 (it) 2021-11-12
DK3628680T3 (da) 2021-10-11
US20190119328A1 (en) 2019-04-25
LT3154561T (lt) 2019-11-25
ZA202001859B (en) 2021-04-28
WO2015191951A3 (en) 2016-03-03
US11965040B2 (en) 2024-04-23
EP3973994A1 (en) 2022-03-30
MX2016016449A (es) 2017-08-24
CY2024015I2 (el) 2024-12-13
IL273746A (en) 2020-05-31
ZA201900497B (en) 2019-10-30
US10562934B2 (en) 2020-02-18
KR20170003993A (ko) 2017-01-10
JP2020128417A (ja) 2020-08-27
US20180371019A1 (en) 2018-12-27
JP2019048834A (ja) 2019-03-28
RU2016147080A3 (enExample) 2018-06-01
CA3241273A1 (en) 2015-12-17
US10435438B2 (en) 2019-10-08
US20200002380A1 (en) 2020-01-02
RU2018136750A3 (enExample) 2021-10-19
KR102346228B1 (ko) 2022-01-04
PT3628680T (pt) 2021-10-07
RU2016147080A (ru) 2018-06-01
US20200123202A1 (en) 2020-04-23
IL281264B (en) 2022-05-01
CN111187338A (zh) 2020-05-22
MX2021009309A (es) 2021-10-26
SI3154561T1 (sl) 2019-11-29
NO2024023I1 (no) 2024-05-24
JP2022034057A (ja) 2022-03-02
HRP20211561T1 (hr) 2021-12-24
CN119236050A (zh) 2025-01-03

Similar Documents

Publication Publication Date Title
BR112016018088A2 (enExample)
BR112016018935A2 (enExample)
BR112016016195A2 (enExample)
BR112016016552A2 (enExample)
BR112016018633A2 (enExample)
BR112016013761A2 (enExample)
BR112016014949A2 (enExample)
BR112016018369A2 (enExample)
BR112016012874A2 (enExample)
BR112015021650A2 (enExample)
BR112016016127A2 (enExample)
BR112016018871A2 (enExample)
BR112016017083A2 (enExample)
BR112016016451A2 (enExample)
BR112016008129A2 (enExample)
BR112016015695A2 (enExample)
BR112016018575A2 (enExample)
BR112016017413A2 (enExample)
BR112016016329A2 (enExample)
BR112016015798A2 (enExample)
BR112016018252A2 (enExample)
BR112016017960A2 (enExample)
BR112016015510A2 (enExample)
BR112016004754A2 (enExample)
BR112016016268A2 (enExample)